Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 15/20 | 0.59 |
| ▸ | CA9 | Q16790 | 7/20 | 0.59 |
| ▸ | CA12 | O43570 | 6/20 | 0.59 |
| ▸ | CA1 | P00915 | 6/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1805614 | 0.94 | LMNA (0.64) | LMNACA2CA9CA12CA1 | |
| SCHEMBL8349082 | 0.83 | LMNA (0.67) | LMNACA2CA9CA12CA1 | |
| SCHEMBL30467547 | 0.82 | LMNA (0.58) | LMNAMEN1KMT2AKDM4ERAB9A | |
| SCHEMBL1433386 | 0.82 | LMNA (0.58) | LMNAMEN1KMT2AKDM4ERAB9A | |
| SCHEMBL31539224 | 0.82 | LMNA (0.58) | LMNAMEN1KMT2AKDM4ERAB9A | |
| SCHEMBL9839080 | 0.80 | LMNA (0.82) | LMNACA2CA9CA12CA1 | |
| Betanaphthol SCHEMBL10765809 | 0.80 | CA2 (0.67) | LMNACA2CA9CA12CA1 | |
| SCHEMBL1432949 | 0.80 | LMNA (0.56) | LMNAMEN1KMT2AKDM4ERAB9A | |
| SCHEMBL1432947 | 0.80 | PTPN1 (0.50) | LMNAMEN1KMT2ARAB9AESR1 | |
| SCHEMBL1771133 | 0.80 | MEN1 (0.47) | LMNACA2CA9CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| CN-103732589-B | Can be used as the sulphonamide of the replacement of anti-apoptotic BCL inhibitor | BRISTOL-MYERS SQUIBB CO. (US) | 2016-03-30 | — | — | CN | disclosed |
| EP-2714681-B1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-06-24 | — | — | EP | disclosed |
| EP-2714681-B1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-06-24 | — | — | EP | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
| US-8404036-B2 | Water-soluble near-infrared absorbing coloring matters and aqueous inks containing same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-03-26 | — | — | US | disclosed |
| WO-2012162365-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012162365-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20110123784-A1 | WATER-SOLUBLE NEAR-INFRARED ABSORBING COLORING MATTERS AND AQUEOUS INKS CONTAINING SAME | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | LMNA 2227/4885CA2 1416/4885CA9 2692/4885 |
| US-20110123784-A1 | WATER-SOLUBLE NEAR-INFRARED ABSORBING COLORING MATTERS AND AQUEOUS INKS CONTAINING SAME | IK, RB1, COL1A1 | LMNA 1431/4885CA2 1279/4885CA9 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.